Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Your research
Source: nct - Country: France,Spain,United Kingdom,Israel,Korea, Republic of,Australia,Italy,Switzerland,Germany - Phase: complete
nct
Update Il y a 5 ans
BUILD 3: Bosentan Use in Interstitial Lung Disease
BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, event-driven, group sequential, phase III superiority study. The primary objective is to demonstrate that bosentan delays disease worsening or death in patients with Idiopathic Pulmonary Fibrosis.
Country
Australia
,
Austria
,
Belgium
,
Canada
,
Croatia
,
Czech Republic
,
France
,
Germany
,
Ireland
,
Israel
,
Italy
,
Japan
,
Korea, Republic of
,
Netherlands
,
Serbia
,
Spain
,
Switzerland
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
Optimal Timing of Dronedarone Initiation After Conversion in Patients With Persistent Atrial Fibrillation
Primary Objective: - Evaluate the rate of Atrial Fibrillation (AF) recurrences one month after randomization according to different timings of initiation of dronedarone. Secondary Objective: - Evaluate the rate of AF recurrences two months after randomization. - Assess the safety of the change from amiodarone to dronedarone - Assess dronedarone safety - Explore dronedarone and its active metabolite plasma level (in a subset of countries) - Explore potential Pharmacokinetic (PK) interaction between dronedarone and amiodarone (in a subset of countries)
Country
Australia
,
Austria
,
Estonia
,
Finland
,
France
,
Germany
,
Israel
,
Italy
,
Korea, Republic of
,
Mexico
,
Netherlands
,
Portugal
,
Spain
,
Switzerland
,
Taiwan, Province of China
,
United Kingdom
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis (IPF).
Country
Australia
,
Belgium
,
Canada
,
Czech Republic
,
France
,
Germany
,
Ireland
,
Israel
,
Italy
,
Japan
,
Korea, Republic of
,
Spain
,
Switzerland
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
1